Haili Bio disclosed the 2021 annual performance pre-increase announcement, it is expected that the net profit attributable to the shareholders of the listed company in 2021 will be between 53 million yuan and 63 million yuan, an increase of 493.73% to 605.75% year-on-year; it is expected that the net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses will be between 21 million yuan and 29 million yuan, an increase of 240.80% to 294.43% year-on-year.
The chairman of the company is Zhang Yue. Ms. Zhang Yue: Born in 1989, Chinese nationality, French permanent residency, master's degree, graduated from the Paris Ecole Supérieure des Sciences, Technology and Economics and Business (ISTECParis), Bachelor's degree in Economics and Management, bachelor's degree, master's degree, postgraduate degree. He is currently the chairman of the board of directors of the company, and also serves as the director of Shanghai Jiemen Biotechnology Co., Ltd., the director of Shandong Haili Biological Products Co., Ltd., the director of Hangzhou Shuchen Biotechnology Co., Ltd., and the partner of Suzhou Tonghe Venture Capital Partnership (Limited Partnership), the partner of Suzhou Tonghe Phase II Venture Capital Partnership (Limited Partnership), and has rich experience in investment and financing and enterprise management.
The above content is compiled by Securities Star based on public information, if you have any questions, please contact us.